Literature DB >> 28121307

Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.

D Scherman1,2,3,4, A Rousseau1,2,3,4, P Bigey1,2,3,4, V Escriou1,2,3,4.   

Abstract

In the RNA interference process, the catalytic degradation of an endogenous mRNA results from the Watson-Crick complementary recognition by either a small silencing synthetic double-stranded ribonucleotide (siRNA) or by a small hairpin RNA (shRNA) produced in the cell by transcription from a DNA template. This interference process ideally results in an exquisitely specific mRNA suppression. The present review is dedicated to siRNAs. It describes the mechanism of RNA silencing and the main siRNA delivery techniques, with a focus on siRNA self-complexing to cationic lipids to form nanoparticles, which are called lipoplexes. The addition to lipoplexes of an anionic polymer leads to the ternary formulation APIRL (Anionic-Polymer-Interfering-RNA-Lipoplexes) with increased in vivo stability and biological efficacy. In terms of clinical development, the review focuses on therapeutic applications by intravenous delivery to the liver and inflammatory joints, and to localized siRNA delivery to the ocular sphere.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28121307     DOI: 10.1038/gt.2017.6

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  37 in total

1.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

2.  Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes.

Authors:  Anne Schlegel; Céline Largeau; Pascal Bigey; Michel Bessodes; Kristell Lebozec; Daniel Scherman; Virginie Escriou
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

Review 3.  Chemical modification of siRNAs for in vivo use.

Authors:  Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-12

Review 4.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

5.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

6.  Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA.

Authors:  J P Yang; L Huang
Journal:  Gene Ther       Date:  1997-09       Impact factor: 5.250

Review 7.  Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA.

Authors:  Kai K Ewert; Alexandra Zidovska; Ayesha Ahmad; Nathan F Bouxsein; Heather M Evans; Christopher S McAllister; Charles E Samuel; Cyrus R Safinya
Journal:  Top Curr Chem       Date:  2010

8.  RNA interference targeting Fas protects mice from fulminant hepatitis.

Authors:  Erwei Song; Sang-Kyung Lee; Jie Wang; Nedim Ince; Nengtai Ouyang; Jun Min; Jisheng Chen; Premlata Shankar; Judy Lieberman
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

9.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

10.  Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells.

Authors:  Yusuke Sato; Hiroto Hatakeyama; Mamoru Hyodo; Hideyoshi Harashima
Journal:  Mol Ther       Date:  2015-12-18       Impact factor: 11.454

View more
  10 in total

1.  The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.

Authors:  Annabelle Biscans; Andrew Coles; Dimas Echeverria; Anastasia Khvorova
Journal:  J Control Release       Date:  2019-03-30       Impact factor: 9.776

Review 2.  'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.

Authors:  Mei S Ong; Wanpei Cai; Yi Yuan; Hin C Leong; Tuan Z Tan; Asad Mohammad; Ming L You; Frank Arfuso; Boon C Goh; Sudha Warrier; Gautam Sethi; Nicholas S Tolwinski; Peter E Lobie; Celestial T Yap; Shing C Hooi; Ruby Y Huang; Alan P Kumar
Journal:  Br J Pharmacol       Date:  2017-08-23       Impact factor: 8.739

Review 3.  Organic dots (O-dots) for theranostic applications: preparation and surface engineering.

Authors:  Amin Shiralizadeh Dezfuli; Elmira Kohan; Sepand Tehrani Fateh; Neda Alimirzaei; Hamidreza Arzaghi; Michael R Hamblin
Journal:  RSC Adv       Date:  2021-01-11       Impact factor: 3.361

4.  Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery.

Authors:  Byungji Kim; Michael J Sailor
Journal:  J Vis Exp       Date:  2019-04-16       Impact factor: 1.355

5.  Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.

Authors:  Bruno M D C Godinho; James W Gilbert; Reka A Haraszti; Andrew H Coles; Annabelle Biscans; Loic Roux; Mehran Nikan; Dimas Echeverria; Matthew Hassler; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2017-10-12       Impact factor: 5.486

Review 6.  Innovative approaches for treatment of osteosarcoma.

Authors:  Emel Rothzerg; Abigail L Pfaff; Sulev Koks
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-19

Review 7.  Strategies for Oligodendrocyte and Myelin Repair in Traumatic CNS Injury.

Authors:  Anne Huntemer-Silveira; Nandadevi Patil; Megan A Brickner; Ann M Parr
Journal:  Front Cell Neurosci       Date:  2021-01-11       Impact factor: 5.505

8.  Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA.

Authors:  Hongjia Zhang; Ke Men; Congbin Pan; Yan Gao; Jingmei Li; Sibei Lei; Guonian Zhu; Rui Li; Yuquan Wei; Xingmei Duan
Journal:  Int J Nanomedicine       Date:  2020-12-07

9.  In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells.

Authors:  Daniel P Feldmann; Yilong Cheng; Rima Kandil; Yuran Xie; Mariam Mohammadi; Hartmann Harz; Akhil Sharma; David J Peeler; Anna Moszczynska; Heinrich Leonhardt; Suzie H Pun; Olivia M Merkel
Journal:  J Control Release       Date:  2018-02-20       Impact factor: 9.776

10.  Advances in the Formulation and Assembly of Non-Cationic Lipid Nanoparticles for the Medical Application of Gene Therapeutics.

Authors:  Richard K Fisher; Phillip C West; Samuel I Mattern-Schain; Michael D Best; Stacy S Kirkpatrick; Raymond A Dieter; Joshua D Arnold; Michael R Buckley; Michael M McNally; Michael B Freeman; Oscar H Grandas; Deidra J H Mountain
Journal:  Nanomaterials (Basel)       Date:  2021-03-23       Impact factor: 5.076

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.